en 
News and Events
View the news highlights below to learn more about the TechEmerge program and current pilots!
TechEmerge Brazil Health Innovation Summit
Events | June 28, 2019
A special thank you to the TechEmerge Program Partners: the Finnish Ministry of Employment and the Economy
MobileODT launched their first wide-scale deployment of AI screening for cervical cancer
News | January 08, 2019
CHENNAI, India, January 8, 2019 /PRNewswire/ --
MobileODT, developer of the Enhanced Visual Assessment (EVA) System, will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared smart mobile colposcope in India to perform the first large-scale pilot of Augmented Intelligence (AI) for use in cervical cancer screening. This will give healthcare professionals cutting edge, yet low-cost mobile technology to reach millions of women across India who previously had limited access to life saving cervical exams.
Max Healthcare and Vios Medical launch monitoring system
News | March 27, 2018
Senior VP, Max Healthcare Vaibhav Poddar excited to announce successful Vios Medical roll-out.
24x7 ward monitoring system launched
News | March 01, 2018
Max Healthcare has partnered with the United States-based Vios Medical for the launch of a 24x7 intelligent vital monitoring system.
Max Healthcare to introduce 24x7 ward monitoring system
News | March 01, 2018
New Delhi, To bring Intensive Care Unit (ICU)-standard monitoring across general wards, Max Healthcare on Wednesday announced a partnership with US-based medical technology company Vios Medical to launch a continuous vital monitoring system built on a medical-grade Internet of Things (IoT) framework.
Zilico Announces $19M from New Investments
News | February 05, 2018
Zilico Ltd continues its global expansion plans for ZedScan™ by securing a strategic deal with the MaxHealth Medicine Group (China), stock code: 836163 (NEEQ). The deal will allow MaxHealth to sell and market ZedScan™, Zilico’s cervical cancer diagnostic system, to the Chinese market.
WellDoc, Voluntis to work together on combined offering for type 2 diabetes
News | January 11, 2018
WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future.
How a Tragic Oversight Led These Two 20-Somethings to Build a Lifesaving Tech Startup
News | January 04, 2018
Stasis Labs found its first market overseas. What's its best next move?
Positive outcomes from WellDoc's BlueStar translate to cost savings, analysis finds
News | January 04, 2018
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.
